Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

0:00-19:08

Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.

Publisher

BioSpace

Published

August 19, 2026

Duration

19 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#amylyxsredemption #summitssurvivalwoes #definiumsanxietywin #lifesciences

The Nile